Aytu bioscience, inc (AYTU)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Feb'15Nov'14May'14Feb'14Nov'13Aug'13May'13Feb'13Nov'12Aug'12May'12Feb'12Nov'11Aug'11May'11Feb'11Nov'10
Net loss

-

-

-28,614

-

-

-

-9,389

-10,187

-17,484

-19,884

-21,028

-22,508

-31,055

-33,113

-31,628

-28,180

-12,892

-5,634

0

0

0

-61

-62

-53

-57

-64

-63

-59

-59

-113

-121

-138

-136

0

0

0

Adjustments to reconcile net loss to cash used in operating activities
Issuance of restricted stock

-

-

-

-

-

-

-

-

227

671

721

724

655

156

75

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation, amortization and accretion

4,533

3,653

3,039

2,727

2,590

2,506

2,494

2,591

4,076

3,956

4,195

4,364

2,705

2,355

1,567

874

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense and restricted stock issuance

890

1,003

1,035

1,022

1,031

667

553

596

548

1,352

1,653

2,502

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Loss) / gain from change in fair value of contingent consideration

-

-

-

-

-

-

-

-

-

-

-

-

250

261

-83

-12

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of prepaid research and development - related party (Note 9)

-

-

-

-

-

-

-

-

-

-

-

335

365

121

121

121

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on investment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on investment

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Compensation through issuance of stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock to employee

-

-

-

-

-

-

-

-

-

-

-

509

0

0

509

-

0

0

0

-

-

-

-

-

2

0

0

0

0

60

60

60

60

0

0

0

Derivative income

17

14

35

80

91

3,234

3,731

3,983

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of warrants to initial investors

-

-

-

-

-

-

-

-

-

-

-

596

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

4

4

4

4

5

5

5

6

6

6

6

6

0

0

0

Contributed capital to fund expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

0

-

-

-

8

7

5

4

5

4

0

0

0

Changes in operating assets and liabilities:
(Increase) in accounts receivable

8,548

3,714

945

1,162

643

105

-451

50

379

784

691

355

258

293

341

5

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Increase) in inventory

255

-72

70

101

646

265

138

26

-332

-42

-397

-195

-387

-214

91

485

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Increase) in prepaid expenses and other

1,764

184

-163

517

-92

179

474

129

554

328

-291

95

-601

-304

192

-155

565

363

0

0

0

-0

-0

-0

-0

0

0

-0

-0

-0

-0

-0

0

0

0

0

(Increase) decrease in security deposits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

(Decrease) in accounts payable and other

-4,586

2,689

419

134

-1,268

-982

442

-109

1,768

1,813

42

493

340

629

710

698

51

-121

0

0

0

1

15

6

6

5

13

10

8

5

4

2

1

0

0

0

Increase in accrued liabilities

6,964

346

722

961

732

689

-474

-596

-839

-701

204

-414

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase in accrued compensation

329

42

205

308

-106

-93

116

200

52

317

148

-861

57

26

-84

1,004

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase in interest payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Decrease) in deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

2

0

0

-10

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Decrease) in deferred rent

-

0

-3

-

-

-4

-6

-6

0

0

0

-

-

-

-

-511

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-24,083

-15,871

-14,074

-13,831

-14,900

-15,668

-14,466

-15,940

0

0

0

-

-

-

-

-

-

-

-

0

0

-34

-35

-35

-37

-45

-35

-35

-37

-34

-46

-63

-64

0

0

0

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-13,225

-13,218

-13,832

-10,657

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows used in investing activities
Deposit

0

0

0

-2

-0

-0

-0

2

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of fixed assets

0

46

53

59

59

75

80

74

132

78

106

111

102

172

254

252

203

125

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Contingent consideration payment

247

559

547

505

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Notes receivable

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of assets

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of assets

5,850

4,200

200

500

0

0

0

-

-

-

-

750

1,250

1,250

1,540

1,040

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-5,706

-6,156

-1,800

-1,061

-1,368

-1,332

-787

-484

0

0

0

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-8,635

-7,435

-5,805

-5,303

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock to Lincoln Park

-

-

-

-

-

-

-

-

-

-

-

739

631

631

631

0

0

15

0

0

0

17

0

0

5

5

9

17

18

30

31

44

43

0

0

0

Issuance costs related to preferred, common stock and warrants

-

-

-

-

-

-

-

-

-

-

-

90

24

24

24

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of preferred, common stock and warrants

-

-

-

-

-

-

-

11,839

24,740

11,839

11,839

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance costs related to preferred, common stock and warrants

-

-

-

-

-

-

-

1,402

2,697

1,402

1,402

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquisition costs included in accounts payable

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Exchange of convertible preferred stock into common stock

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrants issued to investors and underwriters (see Note 6)

-

-

-

-

-

-

-

-

4,117

4,117

4,117

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Earn-out payment to Nuelle Shareholders

-

-

-

-

-

-

-

250

250

250

11

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

8

-3

-0

1

0

2

-1

-3

-6

-5

0

2

0

0

0

Cash paid during the period for Income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Cash paid during the period for Interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

2

2

2

2

0

0

0

Proceeds from convertible promissory notes, net (Note 8)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,175

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Debt issuance costs (Note 8)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

298

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from convertible note from Ampio converted to stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

22

29

32

31

40

28

17

16

7

21

33

35

0

0

0

Fixed assets included in accounts payable

-

-

-

-

-

-

-

-

-

-

-

10

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments on related party loans

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

1

11

13

13

12

0

0

0

Net cash provided by financing activities

77,558

9,633

19,075

19,075

18,934

30,922

12,222

22,659

0

0

0

-

-

-

-

-

-

-

-

0

0

43

32

35

39

45

38

34

33

27

40

64

67

0

0

0

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

16,741

15,000

12,393

16,662

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash, restricted cash and cash equivalents

47,768

-12,394

3,199

4,181

2,665

13,921

-3,032

6,234

8,536

-1,321

4,272

-7,176

-5,120

-5,654

-7,244

701

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosures of cash and non-cash investing and financing transactions
Cash paid for interest

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of right-to-use asset and related lease liability

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contingent consideration included in accounts payable

41

58

46

42

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Primsol accretion included in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fixed assets included in accounts payable

-

-

-

-

-

-

-

-

-

-

-

10

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant derivative liability related to the issuance of the convertible promissory notes (Note 8)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

102

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Primsol asset purchase included in Primsol payable, $1,250,000 less future accretion of $173,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock issued for services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

60

60

60

60

0

0

0